Scorpius Holdings Commends Congress on Bipartisan Legislative Action Aimed at Bolstering U.S. Biomanufacturing
16 Mayo 2024 - 7:00AM
Scorpius Holdings, Inc (NYSE
American: SCPX) (“Scorpius” or “the
Company”), an integrated contract development and manufacturing
organization providing state-of-the-art large molecule contract
development and manufacturing organization (“CDMO”), today
applauded on-going legislative efforts within the United States
Congress to bolster domestic biomanufacturing in the face of
vulnerabilities from America’s adversaries.
The most notable legislative effort is the
recent introduction of the BIOSECURE Act, which would mark a
significant step forward in strengthening America’s pharmaceutical
supply chain and reducing dependency on foreign manufacturers. The
BIOSECURE Act is now seeing significant bipartisan momentum in
Congress, advancing out of the House Oversight Committee this week,
setting the stage for a possible vote and final passage by the end
of the year.
Other notable efforts include recent legislative
and policy measures that prioritize U.S. Government investment and
development for U.S.-based biomanufacturing, as well as the launch
of the BioMaP Consortium within the Biomedical Advanced Research
and Development Authority, of which Scorpius is a member.
Over the past year, Scorpius has proactively
expanded its production facilities, all within the United States,
investing heavily in state-of-the-art technologies to support
scalable and secure manufacturing processes. This expansion not
only enhances the Company's capacity to meet growing demand but
also aligns seamlessly with the objectives of the newly proposed
legislative measures.
Scorpius continues to support ongoing work on
behalf of U.S. Government-backed pharmaceutical programs and
recently hosted several visits to its San Antonio facility from
U.S. Government representatives in which these efforts were
discussed.
Jeff Wolf, CEO of Scorpius, praised the pending
Congressional action, but urged its final passage, stating, “We are
at a critical juncture in ensuring the health security of our
nation. The recent legislative developments, including the
BIOSECURE Act, are commendable as they align with our vision of a
robust, self-reliant American biomanufacturing infrastructure. We
urge Congress to immediately pass the BIOSECURE Act, to ensure that
America’s drug supply chain is no-longer beset with vulnerabilities
from our nation’s adversaries. We are also closely engaged in the
reauthorization of the Pandemic and All-Hazards Preparedness Act,
and strongly urge Congress to pass this critical legislation that
bolsters preparedness in the face of threats. From cancer
treatments to biodefense, it is imperative that we have control
over our pharmaceutical supply chain to protect and provide for the
American people.”
“Scorpius is committed to working with
lawmakers, industry partners, and drug developers to implement the
BIOSECURE Act and other initiatives aimed at onshoring drug
production. By leveraging our enhanced production capabilities and
deep expertise in biomanufacturing, Scorpius stands ready to
support the nation’s healthcare needs while fostering American
economic growth and innovation,” concluded Mr. Wolf.
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated CDMO
focused on manufacturing biologic and cell therapy programs for our
clients. Scorpius offers a broad array of analytical testing,
process development, and manufacturing services to pharmaceutical
and biotech companies at its state-of-the-art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements such as the BIOSECURE Act marking a significant step
forward in strengthening America’s pharmaceutical supply chain and
reducing dependency on foreign manufacturers, a possible vote and
final passage of the BIOSECURE Act by the end of the year. by the
end of the year, continuing to support on-going work on behalf of
U.S. Government-backed pharmaceutical programs. Important factors
that could cause actual results to differ materially from current
expectations include, among others, the passage of the BIOSECURE
Act and its impact on the Company, Company’s ability to expand its
large molecule biomanufacturing CDMO services, attract new
customers, the ability to capture a meaningful market share; the
Company’s financing needs, its cash balance being sufficient to
sustain operations and its ability to raise capital when needed,
the Company’s ability to leverage fixed costs and achieve long-term
profitability; the Company’s ability to obtain regulatory approvals
or to comply with ongoing regulatory requirements, regulatory
limitations relating to the Company’s ability to successfully
promote its services and compete as a pure- play CDMO, and other
factors described in the Company’s annual report on Form 10-K for
the year ended December 31, 2023, and any other filings the Company
makes with the SEC. The information in this presentation is
provided only as of the date presented, and the Company undertakes
no obligation to update any forward-looking statements contained in
this presentation on account of new information, future events, or
otherwise, except as required by law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017ir@scorpiusbiologics.com
Scorpius (AMEX:SCPX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Scorpius (AMEX:SCPX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024